

TABLE 1

	<u>Healthy</u>	<u>CLD (non-cirrhotic)</u>	<u>CLD (cirrhosis)</u>	<i>Statistic¹</i>
Individuals				
<i>Individuals [N] (% of study cohort)</i>	19 (42.2)	11 (24.5)	15 (33.3)	-
<i>Individuals [N] (% of all CLD patients – n=35)</i>	-	11 (42.3)	15 (57.7)	-
Characteristics				
<i>Male [N] (% of sub-group)</i>	12 (63.2)	6 (54.5)	10 (66.7)	NS
<i>Age [years] (range; SD)</i>	39.4 (27-72, 14.0)	55.8 (44-79, 10.4)	54.8 (19-80, 17.7)	NS
<i>BMI [kg/m²] (range; SD)</i>	24.5 (21-30, 2.6)	28.1 (22-38, 5.6)	24.2 (17-33, 4.3)	NS
<i>MELD score [points] (range; SD)</i>	- ^a	10 (5-19, 4.5)	11.6 (7-19, 4.0)	NS
<i>PPI [N] (% of sub-group)</i>	0	11 (100)	15 (100)	NS
CLD etiology				
<i>HCV [N] (% of sub-group)</i>	0	-	4 (26.6)	-
<i>HBV [N] (% of sub-group)</i>	0	-	1 (6.7)	-
<i>ALD [N] (% of sub- group)</i>	0	-	4 (26.6)	-
<i>NAFLD/NASH [N] (% of sub- group)</i>	0	1 (9.1)	-	-
<i>AIH [N] (% of sub- group)</i>	0	7 (63.6)	4 (26.7)	-
<i>PSC [N] (% of sub- group)</i>	0	1 (9.1)	1 (6.7)	-
<i>PBC [N] (% of sub- group)</i>	0	-	1 (6.7)	-
<i>Familial hepatocellular cholestasis [N] (% of sub- group)</i>	0	1 (9.1)	-	-
<i>Cryptogenic liver disease [N] (% of sub- group)</i>	0	1 (9.1)	-	-
Biochemistry				
<i>Creatinine [mg/dl] (range; SD)</i>	- ^a	1.0 (1.0-1.1, 0.0)	1.2 (1.0-2.3, 0.4)	NS
<i>Bilirubin [mg/dl] (range; SD)</i>	- ^a	4.0 (0.5-20.4, 6.4)	2.7 (0.5-15.0, 3.7)	NS
<i>INR (range; SD)</i>	- ^a	1.0 (0.9-1.3, 0.1)	1.1 (0.9-1.6, 0.2)	NS
<i>ALT [U/l] (range; SD)</i>	- ^a	455.9 (17-1666, 649.3)	192.5 (14-2228, 564.8)	NS
<i>AST [U/l] (range; SD)</i>	- ^a	283.2 (19-878, 353.4)	138.5 (21-1303, 323.6)	NS
<i>CRP [mg/l] (range; SD)</i>	- ^a	6.8 (2.3-14.8, 4.5)	9.6 (0.5-36.9, 12.1)	NS
<i>Leucocytes [G/l] (range; SD)</i>	- ^a	6.9 (2.8-14.5, 3.4)	5.5 (2.1-9.5, 2.6)	NS
<i>Thrombocytes [G/l] (range; SD)</i>	- ^a	254.4 (183-364, 60.1)	151.7 (41-380, 102.1)	*